The European Medicines Agency has cautioned countries across the EU from rushing through authorization of Covid-19 vaccines, urging them to await the completion of their own regulatory mechanism.

On Wednesday morning, the UK announced that it had issued emergency authorization for the Pfizer-BioNTech Covid-19 vaccine, making it the first nation to approve the widespread use of a coronavirus jab.

While the news was met with praise domestically, with Health Secretary Matt Hancock saying he was thrilled at its swift approval, authorities and lawmakers in the EU have criticized the speeded-up move.

Also on UK becomes first country to approve Pfizer-BioNTech vaccine against Covid-19

The European Medicines Agency responded to the UK’s decision by stating that the “EMA considers that the conditional marketing authorization is the most appropriate regulatory mechanism for use in the current pandemic emergency.” The EMA’s justification is that the European process is based on more evidence and checks than the UK’s emergency procedure. (RT)